PD-1 Inhibitor or PD-1 Inhibitor Plus GVD for Relapsed/Refractory CHL

  • End date
    Apr 26, 2025
  • participants needed
  • sponsor
    Sun Yat-sen University
Updated on 26 April 2021


This phase 2 trial studies the efficacy and safety of PD-1 inhibitor monotherapy or PD-1 inhibitor with GVD (Gemcitabine, Vinorelbine and Doxorubicin Liposome) regimen for relapsed or refractory classical Hodgkin lymphoma (CHL) patients who failed the first-line induction therapy.

Condition Classical Hodgkin Lymphoma, Refractory or Relapsed Classical Hodgkin Lymphoma
Treatment PD-1 Inhibitor, PD-1 inhibitor, gemcitabine, vinorelbine and doxorubicin liposome
Clinical Study IdentifierNCT04624984
SponsorSun Yat-sen University
Last Modified on26 April 2021


Yes No Not Sure

Inclusion Criteria

Histologically confirmed classical Hodgkin lymphoma
Refractory to or relapsed after first-line induction therapy; prior radiotherapy is allowed
At least one evaluable lesion according to 2014 Lugano criteria
Life expectancy > 3 months
Eastern Cooperative Oncology Group (ECOG) of 0-1
Able to participate in all required study procedures
Proper functioning of the major organs: 1) The absolute value of neutrophils (>1.510^9/L); 2) platelet count (> 7510^9/L); 3) Hemoglobin (> 80 g/L); 4) Serum creatinine <1.5 times Upper Limit Normal (ULN) ; 5) Serum total bilirubin < 1.5 times ULN; 6) Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) < 2.5 times ULN; 7) Coagulation function: International Normalized Ratio (INR), Prothrombin Time (PT), Activated Partial Thromboplastin Time (APTT) < 1.5 times ULN (unless the subject is receiving anticoagulant therapy and PT and APTT are within the expected range at screening time). ; 8) Thyrotropin (TSH) or free thyroxine (FT4) or free triiodothyronine (FT3) were all within the normal range (10%)
There was no evidence that subjects had difficulty breathing at rest, and the measured value of pulse oximetry at rest was more than 92%
Volunteers who signed informed consent

Exclusion Criteria

Involvement of central nervous system (CNS)
Previously received treatment of immune checkpoint inhibitors (eg. PD-1, PD-L1, CTLA-4)
Previously received treatment of hematopoietic cell transplantation
Patients with Hemophagocytic syndrome
Patients with active autoimmune diseases requiring systematic treatment in the past two years (hormone replacement therapy is not considered systematic treatment, such as type I diabetes mellitus, hypothyroidism requiring only thyroxine replacement therapy, adrenocortical dysfunction or pituitary dysfunction requiring only physiological doses of glucocorticoid replacement therapy); Patients with autoimmune diseases who do not require systematic treatment within two years can be enrolled
Requiring treatment with corticosteroids or other immunosuppressive drugs within 14 days of study drug administration [allowing subjects to use local, ocular, intra-articular, intranasal and inhaled glucocorticoid therapy (with very low systemic absorption); and allowing short-term (< 7 days) glucocorticoid prophylaxis (e.g., contrast agent overdose sensitivity) or for the treatment of non-autoimmune diseases (e.g. delayed hypersensitivity caused by contact allergens)
Uncontrolled active infection, with the exception of tumor-related B symptom fever
History of human immunodeficiency virus (HIV) infection and/or patients with acquired immunodeficiency syndrome are known
Patients with active hepatitis B or active hepatitis C. Patients who are positive for hepatitis B Surface Antigen (HBsAg) or hepatitis C Virus (HCV) antibodies at screening stage must pass further detection of hepatitis B Virus (HBV) DNA (no more than 10^4 copies/mL) and HCV RNA (no more than the lower limit of the detection method) in the row. Hepatitis B carriers, stable hepatitis B (DNA titer should not be higher than 10^4 copies/mL) after drug treatment, and cured hepatitis C patients can be enrolled in the group
Diagnosed with or receiving treatment for malignancy other than lymphoma
Pregnant or breastfeeding women
Other researchers consider it unsuitable for patients to participate in this study
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note